Coherus BioSciences, Inc. (NASDAQ:CHRS) will issue its quarterly earnings data after the market closes on Tuesday, November 7th.

Coherus BioSciences (NASDAQ:CHRS) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($1.08) EPS for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.21. Coherus BioSciences had a negative net margin of 73.89% and a negative return on equity of 307.41%. The company had revenue of $1.40 million for the quarter. On average, analysts expect Coherus BioSciences to post $-4.34 EPS for the current fiscal year and $-3.13 EPS for the next fiscal year.

Shares of Coherus BioSciences, Inc. (NASDAQ CHRS) opened at 11.50 on Tuesday. The firm’s 50 day moving average is $13.14 and its 200-day moving average is $15.57. Coherus BioSciences, Inc. has a 52-week low of $10.65 and a 52-week high of $30.43. The company’s market capitalization is $590.48 million.

In other Coherus BioSciences news, insider Alan C. Herman sold 17,535 shares of the company’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $15.02, for a total transaction of $263,375.70. Following the transaction, the insider now directly owns 49,651 shares in the company, valued at approximately $745,758.02. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 26.28% of the company’s stock.

A number of equities research analysts have commented on CHRS shares. BidaskClub lowered shares of Coherus BioSciences from a “sell” rating to a “strong sell” rating in a report on Saturday, August 5th. Zacks Investment Research raised shares of Coherus BioSciences from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a report on Tuesday, August 15th. ValuEngine raised shares of Coherus BioSciences from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. J P Morgan Chase & Co reissued an “overweight” rating and set a $25.00 price objective (down previously from $32.00) on shares of Coherus BioSciences in a report on Tuesday, August 8th. Finally, Credit Suisse Group reissued an “outperform” rating and set a $17.00 price objective (down previously from $24.00) on shares of Coherus BioSciences in a report on Wednesday, September 27th. Three investment analysts have rated the stock with a sell rating and nine have assigned a buy rating to the stock. Coherus BioSciences currently has a consensus rating of “Buy” and an average target price of $32.00.

COPYRIGHT VIOLATION WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at

About Coherus BioSciences

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Earnings History for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related companies with's FREE daily email newsletter.